Nichi-Iko Pharmaceutical Co., Ltd. reported consolidated earnings results for the first quarter of fiscal year ending March 31, 2018. For the quarter, sales were JPY 48,513 million against JPY 38,029 million a year ago. Operating profit was JPY 3,180 million against JPY 3,036 million a year ago. Ordinary profit was JPY 3,202 million against JPY 2,526 million a year ago. Quarterly net profit attributable to Parent was JPY 1,964 million against JPY 2,000 million a year ago. Capital expense was JPY 4,195 million against JPY 2,082 million a year ago.

For the first half of fiscal year ending March 31, 2018, the company expects sales of JPY 99,000 million, operating profit of JPY 4,400 million, ordinary profit of JPY 4,200 million and net profit attributable to parent of JPY 2,700 million.

For the fiscal year ending March 31, 2018, the company expects sales of JPY 206,000 million, operating profit of JPY 9,000 million, ordinary profit of JPY 8,600 million, net profit attributable to parent of JPY 5,500 million, capital expense of JPY 10,568 million and depreciation of JPY 10,985 million.